Brief: CohBar Says CohBar Antifibrotic Peptide In Combination With Nintedanib Shows Enhanced Effects In An Idiopathic Pulmonary Fibrosis Model
26/10/2020 13:18
Oct 26 (Reuters) - CohBar Inc CWBR.O :
* COHBAR ANTIFIBROTIC PEPTIDE IN COMBINATION WITH NINTEDANIB
SHOWS
ENHANCED EFFECTS IN AN IDIOPATHIC PULMONARY FIBROSIS MODEL
* COHBAR INC - NEW PRECLINICAL DATA SHOWING COMBINATION OF
CB5138
ANALOG WITH NINTEDANIB PRODUCED ENHANCED EFFECTS COMPARED TO
NINTEDANIB ALONE IN MICE
* COHBAR - NEW DATA FROM IPF THERAPEUTIC MOUSE MODEL SHOWED
TREATMENT WITH CB5138-2, NINTEDANIB COMBINATION PRODUCED GREATER
REDUCTIONS IN FIBROSIS
Source text for Eikon: ID:nGNX9lQylZ
Further company coverage: CWBR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CohBar
See all newsBrief: CohBar, Inc. Q2 EPS USD -1.49
Brief: Morphogenesis And CohBar Announce Positive Results From Phase 1B Trial Of IFX-HU2.0 Personalized Cancer Vaccine, In Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) And Cutaneous Squamous Cell Carcinoma (CSCC)
U.S. STOCKS ON THE MOVE-Galecto, Pinterest, Standard Lithium
CohBar surges on merger agreement with Morphogenesis
U.S. STOCKS ON THE MOVE-Chevron, Broadcom, Williams-Sonoma